Bristol Myers Squibb (CELG-RI) Shareholder's Equity Growth (3y) (2012 - 2026)

Bristol Myers Squibb (CELG-RI) Shareholder's Equity Growth (3y) (2012 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 309.61%
Dec 31, 2025 154.17%
Sep 30, 2025 188.92%
Jun 30, 2025 26.02%
Mar 31, 2025 65.00%
Dec 31, 2024 -14.45%
Sep 30, 2024 -81.25%
Jun 30, 2024 0.00%
Mar 31, 2024 -44.17%
Dec 31, 2023 5.62%
Sep 30, 2023 -17.49%
Jun 30, 2023 -41.07%
Mar 31, 2023 -81.99%
Dec 31, 2022 -26.60%
Sep 30, 2022 -26.98%
Jun 30, 2022 -61.15%
Mar 31, 2022 -83.81%
Dec 31, 2021 528.38%
Sep 30, 2021 47.69%
Jun 30, 2021 -71.35%